ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3016% above fair value
$10.22+0.03 (+0.29%)
Close on Nov 12, 2026Market cap $92.82MP/E 51.1Yield –
ImmuCell gross margin
Gross margin is gross profit as a percentage of revenue.
ImmuCell's gross margin for the twelve months ending Sep 30, 2026 was 40.8%. For fiscal 2025 it was 41.4%, against 30.0% the year before. The highest annual figure on record is 61.1% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.4% | +11.4 |
| FY2024 | Dec 31, 2024 | 30.0% | +7.8 |
| FY2023 | Dec 31, 2023 | 22.1% | −19.0 |
| FY2022 | Dec 31, 2022 | 41.2% | −3.8 |
| FY2021 | Dec 31, 2021 | 45.0% | +0.3 |
| FY2020 | Dec 31, 2020 | 44.7% | −4.4 |
| FY2019 | Dec 31, 2019 | 49.1% | +1.8 |
| FY2018 | Dec 31, 2018 | 47.3% | −2.8 |
| FY2017 | Dec 31, 2017 | 50.1% | −6.7 |
| FY2016 | Dec 31, 2016 | 56.8% | −4.3 |
| FY2015 | Dec 31, 2015 | 61.1% | +2.5 |
| FY2014 | Dec 31, 2014 | 58.6% | +7.6 |
| FY2013 | Dec 31, 2013 | 50.9% | −5.7 |
| FY2012 | Dec 31, 2012 | 56.7% | +1.6 |
| FY2011 | Dec 31, 2011 | 55.1% | +2.6 |
| FY2010 | Dec 31, 2010 | 52.5% | −0.7 |
| FY2009 | Dec 31, 2009 | 53.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 44.2% | +1.3 |
| Q2 FY2026 | Jun 30, 2026 | 33.9% | −9.8 |
| Q1 FY2026 | Mar 31, 2026 | 45.0% | +3.4 |
| Q4 FY2025 | Dec 31, 2025 | 38.2% | +1.6 |
| Q3 FY2025 | Sep 30, 2025 | 42.9% | +16.6 |
| Q2 FY2025 | Jun 30, 2025 | 43.7% | +21.2 |
| Q1 FY2025 | Mar 31, 2025 | 41.6% | +9.9 |
| Q4 FY2024 | Dec 31, 2024 | 36.5% | +13.1 |
| Q3 FY2024 | Sep 30, 2024 | 26.3% | −3.2 |
| Q2 FY2024 | Jun 30, 2024 | 22.5% | +13.8 |
| Q1 FY2024 | Mar 31, 2024 | 31.6% | +6.3 |
| Q3 FY2023 | Sep 30, 2023 | 23.5% | −15.0 |
| Q2 FY2023 | Jun 30, 2023 | 29.5% | −14.7 |
| Q1 FY2023 | Mar 31, 2023 | 8.7% | −43.0 |
| Q4 FY2022 | Dec 31, 2022 | 25.4% | −21.7 |
| Q3 FY2022 | Sep 30, 2022 | 38.5% | −8.5 |
| Q2 FY2022 | Jun 30, 2022 | 44.2% | −1.5 |
| Q1 FY2022 | Mar 31, 2022 | 51.7% | +12.7 |
| Q4 FY2021 | Dec 31, 2021 | 47.0% | +3.7 |
| Q3 FY2021 | Sep 30, 2021 | 47.0% | +0.7 |
| Q2 FY2021 | Jun 30, 2021 | 45.7% | +2.4 |
| Q1 FY2021 | Mar 31, 2021 | 39.0% | −6.5 |
| Q4 FY2020 | Dec 31, 2020 | 43.3% | −7.3 |
| Q3 FY2020 | Sep 30, 2020 | 46.3% | −2.6 |
| Q2 FY2020 | Jun 30, 2020 | 43.3% | −2.8 |
| Q1 FY2020 | Mar 31, 2020 | 45.5% | −4.4 |
| Q4 FY2019 | Dec 31, 2019 | 50.6% | +3.1 |
| Q3 FY2019 | Sep 30, 2019 | 48.9% | +4.7 |
| Q2 FY2019 | Jun 30, 2019 | 46.1% | −3.2 |
| Q1 FY2019 | Mar 31, 2019 | 49.9% | +2.7 |
| Q4 FY2018 | Dec 31, 2018 | 47.5% | +8.8 |
| Q3 FY2018 | Sep 30, 2018 | 44.2% | −2.5 |
| Q2 FY2018 | Jun 30, 2018 | 49.3% | −3.3 |
| Q1 FY2018 | Mar 31, 2018 | 47.2% | −13.5 |
| Q4 FY2017 | Dec 31, 2017 | 38.7% | −16.4 |
| Q3 FY2017 | Sep 30, 2017 | 46.7% | – |
| Q2 FY2017 | Jun 30, 2017 | 52.7% | – |
| Q1 FY2017 | Mar 31, 2017 | 60.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 55.0% | – |
See a number that looks wrong?